ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Triangle's CRO industry saw a flurry of M&A activity over past year
This article provides an overview of the mergers and acquisition activity across 2021 that have involved CROs based or heavily present in the North Carolina Triangle, which includes ICON’s $12bn acquisition of PRA Health Sciences.
Using cross-functional teams to develop a product's value story
Experts from the Commercial Solutions team discuss how essential a data-driven strategy is to successfully communicate a brand’s value proposition in a competitive market.
ICON plc (ICLR) Q4 earnings meet estimates
This article summarises ICON’s quarterly and 2021 year-end financial results.
So what sectors had the most M&A activity?
This article shares how the medical and biotech sectors have dominated the mergers & acquisitions (M&A) landscape and mentions ICON’s acquisition of PRA Health Sciences.
A ‘banner year’ for M&A activity across Ireland
This article provides an overview of the mergers and acquisition activity that took place in Ireland across 2021. This includes ICON’s $12bn acquisition of PRA Health Sciences as one of the “big deals of 2021”.
Two-part series: The evolution of data technology
In this two-part series, Emily Mitchell and Kathleen Mandziuk offer their insights on the evolution of data technology.
Black History Month 2022
A series of interviews in celebration of Black History Month, featuring members of the Black community who work within the field of STEM, as we want to allow more diverse voices to be heard and acknowledge their achievements.
Gene therapy – affordability, access and reimbursement
Brian Huber considers the affordability, access and reimbursement challenges within the gene therapy market.
How CRO venture capital relationships can help biotech fundraising
This article considers how partnering with a CRO can help emerging biotechs to secure funding.
JPM 2022: Decentralised trials, broader service offerings and novel drugs key trends in the CRO space
In this snapshot from the J.P. Morgan Healthcare Conference, Steve Cutler comments on ICON’s success in decentralised trials and therapeutic technologies such as mRNA and checkpoint inhibitors.